G&E’s False Claims Litigation Group has represented whistleblowers in some of the largest qui tam cases brought under federal, state and municipal False Claims Acts. These cases have been a catalyst for exposing unlawful practices that drain government dollars and place consumers at health and safety risk. Blockbuster recoveries include:
Western District of Virginia
G&E’s efforts on behalf of the lead whistleblower against Abbott Laboratories served as a catalyst for a $1.6 billion recovery for federal and state governments. The result marked one of the largest recoveries under the False Claims Act in a pharmaceutical case involving a single drug. The case was initiated when G&E’s False Claims Litigation Group brought claims in the United States District Court for the Western District of Virginia on behalf of the U.S. government and more than two dozen states alleging that Abbott had unlawfully marketed its anti-epileptic drug, Depakote, to children and nursing home patients. In addition to a monetary recovery, the settlement broke ground with a corporate integrity agreement that places compliance burdens on Abbott’s corporate management.
District of South Carolina
In a major whistleblower settlement, G&E, working with the U.S. Department of Justice and the U.S. Attorney’s office in South Carolina, reached an agreement with Amgen in which the drug giant paid $24.9 million to resolve claims that it paid kickbacks to long-term care pharmacies so that elderly patients in nursing homes across the nation would be switched to or placed on the company’s drug, Aranesp. The drug, one of several Erythropoetin stimulating agents (ESAs) on the market, was developed to treat patients with severe anemia whose lives were endangered from receiving frequent blood transfusions. The settlement with the government speaks to the stunning breadth of Amgen’s alleged conduct from September 1, 2003 to December 31, 2011. Specifically, the U.S. alleged that Amgen offered and paid kickbacks to long-term care pharmacy providers for the purpose of inducing them to recommend Aranesp and influence health care providers’ selection and utilization of the drug within the nursing homes, skilled nursing facilities, and long-term care settings. These kickbacks were paid by Amgen as purported market-share rebates, purported volume-based rebates, grants, honoraria, speaker fees, consulting services, dinners, travel, or purchases of unnecessary data.
District of South Carolina / Western District of North Carolina
G&E’s False Claims Litigation Group played a part in the government’s $25 billion recovery in the winter of 2012 against several of the world’s largest banks. G&E represented the whistleblower in a lawsuit against mortgage servicers Bank of America Corporation, J.P. Morgan Chase & Co., Wells Fargo & Company, and Citigroup Inc. The defendants agreed to pay $95 million to resolve allegations that they participated in a pervasive nationwide practice of failing to obtain required mortgage assignments and using false assignments to submit Federal Housing Administration mortgage insurance claims, which resulted in servicing misconduct. G&E worked with the U.S. Attorney’s Office for the District of South Carolina, the U.S. Attorney’s Office for the Western District of North Carolina, the Offices of Inspector General and legal counsel from the U.S. Department of Housing and Urban Development, Treasury and Federal Reserve to achieve this settlement. The whistleblower’s allegations and information also served to aid in the government’s overall blockbuster recovery.
Central District of California
G&E represents the whistleblower in a case against Celgene Corp., a manufacturer of the drugs Thalomid and Revlimid. The suit alleges that Celgene marketed these drugs to cancer patients and their doctors for unapproved purposes, and paid kickbacks to physicians for prescribing the medications, costing the U.S. government and state healthcare payors hundreds of millions of dollars. On July 10, 2014, the defendant’s motion to dismiss was denied, and the case is proceeding to discovery.
District of Massachusetts
G&E represented one of several whistleblowers in a case against pharmaceutical giant GlaxoSmithKline (GSK) that resulted in a $1.04 billion recovery for the federal and state governments. The suit arose from alleged misrepresentation by GSK in its promotion of the company’s popular asthma and Chronic Obstructive Pulmonary Disease (COPD) medication, Advair.
Western District of Kentucky, Paducah Division
G&E is lead counsel for whistleblowers in a case involving a failed cleanup of a government-operated enrichment plant in Kentucky. The U.S. Department of Justice has intervened and the parties are actively litigating the case.
Eastern District of Virginia
G&E’s False Claims Litigation Group represented a whistleblower in a qui tam action involving allegations of price-fixing and bid-rigging by companies providing moving and storage services for U.S. military service members. The whistleblowers, citizens of Germany, came forward and reported the False Claims Act violations to the U.S. Army in 2002, resulting in criminal convictions and fines for federal antitrust violations for a number of moving companies and at least one individual. A partial settlement of the False Claims Act allegations, totaling $13 million, was reached. The case set precedent for a foreign national to seek relief under the U.S. False Claims Act.
District of Massachusetts
G&E’s False Claims Litigation Group represented one of six whistleblowers who revealed information to the government that resulted in an overall $2.3 billion recovery for the federal and state governments.
Western District of Oklahoma
G&E represented two key whistleblowers behind a $257.4 million settlement between drugmaker Wyeth Pharmaceuticals, a subsidiary of Pfizer, and the U.S. Department of Justice stemming from alleged marketing abuses of Wyeth’s powerful immunosuppressant drug Rapamune. The case was originally brought in the U.S. District Court for the Eastern District of Pennsylvania by two whistleblowers, both of whom were sales representatives for the company. Initially, the case was declined by the Justice Department, however, G&E continued to move forward with the case. On September 21, 2010, the Justice Department intervened and transferred the case to the U.S. District Court for the Western District of Oklahoma, where there was an ongoing investigation. The settlement agreement noted the broad scope of Wyeth’s alleged unlawful marketing of Rapamune for well over a decade, spanning from September 1999 to December 2011, including the knowing promotion of Rapamune for uses that were not approved by U.S. Food and Drug Administration. In addition to the civil settlement, the company pled guilty to a violation of the Food Drug and Cosmetics Act and entered into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services. The settlement is one of the largest False Claims Act recoveries for a single drug.